SAN FRANCISCO, Calif. — Synthio Labs, a clinical-grade voice AI company transforming how life sciences organizations engage both clinicians and patients, has raised $5 million in seed funding. The round was led by Elevation Capital with participation from 1984 Ventures, Peak XV Partners, Y Combinator, and strategic angels across the global healthcare and AI ecosystem.
The funding will accelerate Synthio Labs’ mission to build the voice-powered AI operating system for pharmaceutical and healthcare engagement. As life sciences companies spend more than $30 billion each year communicating with physicians and patients, much of the process remains manual, inconsistent, and difficult to scale. Synthio Labs aims to solve this with real-time, compliant voice AI that delivers accurate and accessible medical information, addresses patient support gaps, and reduces treatment drop-off—especially in chronic care.
“We believe Synthio Labs is defining the next major customer-engagement infrastructure for life sciences,” said Krishna Mehra, AI Partner at Elevation Capital. “Their clinical-grade voice AI platform unifies how pharma communicates—giving field teams a powerful voice companion, and giving physicians and patients instant, trusted, compliant answers 24/7.”
Synthio Labs has developed an integrated AI Operating System built around three flagship platforms. Jarvis serves as the clinical-grade voice AI copilot for pharmaceutical field teams. Ather is a multimodal AI engine enabling seamless omnichannel engagement with physicians and patients. Simulation Studio creates high-fidelity digital twins of clinicians and patients to support research, training, and commercial strategy. Together, these tools automate compliant conversations, generate structured intelligence, and deliver consistent, human-grade communication at scale.
“Beyond breakthrough medicines, the future of healthcare will depend on how we reach and support every clinician and patient who relies on them,” said Supreet Deshpande, Co-founder and CEO. “At Synthio, we’re building the AI infrastructure that makes that possible.” Rajashekar Vasantha, Co-founder and CTO, added that the company’s mission is to deliver this support “intelligently, compliantly, and at scale.”
“We’re designing products that make every conversation between pharma and their customers smarter, faster, and more meaningful,” said Sahitya Sridhar, Co-founder and Chief Product Officer. “Our goal is simple: bring consumer-grade experiences to pharma and empower the people delivering care.”
Synthio Labs is already working with several top global pharmaceutical companies and leading direct-to-consumer healthcare brands. One recent project used Synthio’s voice AI to reach more than 5,000 eczema patients in 48 hours, fully automating onboarding, screening, and support.
“It’s been a pleasure working with the Synthio Labs team,” said Rafal Pielak, Founder and CEO of Soteri Skin. “They built a voice AI agent that engaged thousands of eczema patients, completing 5,000 calls in just two days. We’re very happy with the results.”
Founded by Supreet Deshpande, Sahitya Sridhar, and Rajashekar Vasantha, the company draws on deep experience in pharma strategy, AI engineering, and large-scale commercial programs, gained from roles at McKinsey, ZS Associates, Amazon, and Audible. With the new funding, Synthio Labs plans to expand its engineering and product teams, scale enterprise deployments across the United States and Europe, and strengthen partnerships with global life sciences organizations. The company aims to establish AI-driven engagement as the new standard for how pharmaceutical teams support clinicians and patients worldwide.
